CD4-induced epitopes in the HIV envelope glycoprotein, Gp120

Current HIV Research

Volumn 5, Issue 6, 2007, Pages 561-571

  DeVico, Anthony L ^a,b  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

CD4; Coreceptor; Envelope; gp120; HIV

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIGENICITY; ENZYME BINDING; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; STRAIN DIFFERENCE; VIRUS ENVELOPE; VIRUS STRAIN; VIRUS VIRULENCE;

AIDS VACCINES; ANTIGENS, CD4; EPITOPES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38949214786     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207782418560     Document Type: Review

References (106)

1. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehurde S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou T-C, Ruprecht RM. (2000). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Medicine. 6:200-206.
2. Bhattacharya J, Peters PJ, Clapham PR. (2003). CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS. 17(Suppl. 4):S35-43.
3. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. (2004). Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Journal of Virology. 78:13232-13252.
4. Bowley DR, Labrijn AF, Zwick MB, Burton DR. (2007). Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Engineering Design and Selection. 20:81-90.
5. Bublil EM, Yeger-Azuz S, Gershoni JM. (2006). Computational prediction of the cross-reactive neutralizing epitope corresponding to the [corrected] monclonal [corrected] antibody b12 specific for HIV-1 gp120. FASEB Journal. 20:1762-1774.
6. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. (2004). HIV vaccine design and the neutralizing antibody problem. Nature Immunology. 5:233-236.
7. Burton DR, Pyati J, Koduri R, Thornton GB, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Moore JP, Ho DD, Barbas CF, III (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1024-1027.
8. Burton DR, Stanfield RL, Wilson IA. (2005). Antibody vs HIV in a clash of evolutionary titans. Proceedings of the National Academy of Sciences of the United States of America. 102:14943-14948.
9. Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H, Robinson J, van der Groen G, Quinnan GV, Jr. (2006). Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus-type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology. 347:36-51.
10. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. (2005). Structure of an unliganded simian immunodeficiency virus gp120 core. Nature. 433:834-841.
11. Choe H, Li W, Wright PL, Vasilieva N, Venturi M, Huang CC, Grundner C, Dorfman T, Zwick MB, Wang L, Rosenberg ES, Kwong PD, Burton DR, Robinson JE, Sodroski JG, Farzan M. (2003). Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1-gpl20. Cell. 114:161-170.
12. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. (2005). Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. Journal of Virol. 79:6528-6531.
13. Choudhry V, Zhang MY, Harris I, Sidorov IA, Vu B, Dimitrov AS, Fouts T, Dimitrov DS. (2006). Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochemical and Biophysical Research Communications. 348:1107-1115.
14. Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, Bouma P, Cham F, Choudhary A, Rybak SM, Fouts T, Montefiori DC, Broder CC, Quinnan GV, Jr., Dimitrov DS. (2007). Cross-reactive HIV-1 neutralizing monoclonal anti-bodies selected by screening of an immune human phage library against an envelope glycoprotein (gp 140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology. 363:79-90.
15. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. (1996). The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Medicine. 2:1244-1247.
16. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, Jiang P, de Vries RP, Wiley C, Zharkikh I, Schulke N, Roux KH, Monteflori DC, Burton DR, Binley JM. (2007). A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology. 366:245-262.
17. Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, Franti M, Schulke N, Binley JM. (2005). Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Human Antibodies. 14:101-113.
18. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312:763-767.
19. Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, Burton DR, Dimitrov DS, Ji X. (2004). Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry. 43:1410-1417.
20. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn- BH, Kwong PD, Robinson JE, Shaw GM. (2005). Antigenic conservation and immunogenicity of the HIV coreceptor binding site. Journal of Experimental Medicine. 201:1407-1419.
21. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, Stamatatos L. (2006). Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Journal of Virology. 80:8745-8762.
22. Derdeyn CA, Decker JK Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 303:2019-2022.
23. DeVico AL, Rahman R, Welch J, Crowley R, Lusso P, Sarngadharan MG, Pal R. (1995). Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120. Virology. 211:583-588.
24. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR. (2007). Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. Journal of Virology. 81:6548-6562.
25. Edwards TG, Hoffman TL, Baribaud F, Wyss S, LaBranche CC, Romano J, Adkinson J, Sharron M, Hoxie JA, Doms RW. (2001). Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. Journal of Virology. 75:5230-5239.
26. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A, Thomas JF, Stoebenau-Haggarty B, Choe S, Vance PJ, Wells TN, Power CA, Sutterwala SS, Doms RW, Landau NR, Hoxie JA. (1996). CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell. 87:745-756.
27. Finnegan CM, Berg W, Lewis GK, DeVico AL. (2001). Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. Journal of Virology. 75:11096-11105.
28. Finnegan CM, Berg W, Lewis GK, DeVico AL. (2002). Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. Journal of Virology. 76:12123-12134.
29. Fouts TR, Trkola A, Fung MS, Moore JP. (1998). Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. AIDS Research and Human Retroviruses. 14:591-597.
30. Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ, Little SJ, Richman DD. (2005). Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. Journal of Virology. 79:6523-6527.
31. Fung MSC, Sun CRY, goidon WL, Liou R-S, Chang TW, Sun WNC, Daar ES, Ho DD. (1992). Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. Journal of Virology. 66:848-856.
32. Gomez-Roman VR, Florese RH, Peng B. Montefiori DC, Kalyanaraman VS, Venzon D, Srivastava I, Barnett SW, Robert-Guroff M. (2006). An adenovirus-based HIV subtype B prime/boost-vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity againat non-subtype B HIV strains. Journal of the Acquired Immunodeficiency Syndrome. 43:270-277.
33. Gomez-Roman VR, Patterson L., Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M. (2005). Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. Journal of Immunology, 174:2185-2189.
34. Gray ES, Mgore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L. (2007). Neutralizing antibody responses in acute numan immunodeficiency virus type 1 subtype C infection. Journal of Virology. 81:6187-6196.
35. Hahn BH, Gonda MA, Shaw GM, Popovic M, Hoxie JA, Gallo RC, Wong-Staal F. (1985). Genomic diversity of the acquired immune deficiency syndrome, virus HTLV-III: different vinises exhibit greatest divergence in their envelope genes. Proceedings of the National Academy of Sciences of the United States of America. 82:4813-4817.
36. Hart TK, Kirsh R, Ellens H, Sweet RW, Lambert DM, Petteway RS, Jr., Leary J, Bugelski PJ. (1991). Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proceedings of the National Academy of Sciences of the United States of America. 88:2184-2193.
37. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. (2005). V3: HIV's switch-hitter. AIDS Research and Human Retroviruses. 21:171-189.
38. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R,Robinson, J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alain SM. (2005). Cardiolipin-polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 308:1906-1908.
39. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. (2005). Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Human Antibodies. 14:59-67.
40. Heredia A, Gilliam B, Devico A, Le N, Bamba D, Flinko R, Lewis G, Gallo RC, Redfield RR. (2007). CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS. 21:1317-1322.
41. Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR. (2007). Rapamycin reduces CCR5 density levels on CD4 T cells and this effect results in potentiation of Enfluvirtide (T-20) against R5 HIV-1 in vitro. Antimicrobial Agents and Chemotherapy. 51: 2489-2496.
42. Herrera C, Spenlehauer C, Fung MS, Burton DR, Beddows S, Moore JP. (2003). Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. Journal of Virology. 77:1084-1091.
43. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, Hoxie JA, Doms RW. (1999). Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proceedings of the National Academy of Sciences of the United States of America. 96:6359-6164.
44. Hoxie JA, LaBranche CC, Endres MJ, Turner JD, Berson JF, Doms RW, Matthews TJ. (1998). CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. Journal of Reproductive Immunology 41:197-211.
45. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. (2005). Structure of a V3-containing HIV-1 gp120 core. Science. 310:1025-1028.
46. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang MY, Dimitrov DS, Hendrickson WA, Robinson J, Sodroski J, Wyatt R, Choe H, Farzan M, Kwong PD. (2004). Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proceedings of the National Academy of Sciences of the United States of America. 101:2706-2711.
47. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B, Weber R, von Wyl V, Gunthard HF, Trkola A. (2006). Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Medicine. 3:e441.
48. Kolchinsky P, Kiprilov E, Sodroski J. (2001). Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. Journal of Virology. 75:2041-2050.
49. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 420:678-682.
50. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. (1998). Stiucture of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:648-659.
51. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. (2000). Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. Journal of Virology. 74:1961-1972.
52. LaBranche CC, Hoffman TL, Romano J, Haggarty BS, Edwards TG, Matthews TJ, Doms RW, Hoxie JA. (1999). Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. Journal of Virology. 73:10310-10319.
53. LaBranche CC, Hoffman TL, Romano J, Haggarty BS, Edwards TG, Matthews TJ, Donis RW, Hoxie JA. (1999). Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. Journal of Virology. 73:10310-10319.
54. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J. Burton DR. (2003). Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. Journal of Virology. 77:10557-10565.
55. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. (1990). Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. Journal of Biological Chemistry. 265:10373-10382.
56. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gan F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefori DC. (2006). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. Journal of Virology. 80:1776-11790.
57. Liao HX, Alain SM, Mascold JR, Robinson J, Ma B, Monteflori DC, Rhein M, Sutherland LL, Scearce R, Haynes BF. (2604). Immunogenicity of conststrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. Journal of Virology. 78:5270-5278.
58. Martin KA, Wyatt R, Farzan M, Choe H, Marcon L, Desjardins E, Robinson J, Sodroski J, Gerard C, Gerard NP. (1997). CD4-independent binding of SIV gp120 to rhesus CCR5. Science. 278:1470-1473.
59. Wascola IR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. (1999). Protection of macaques against pathogenic simian/human immunodefiency virus 89.6PD by passive transfer of neutralizing antibodies. Journal of Virology. 73:4009-4018.
60. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine. 6:207-210.
61. McLain L, Dimmock NJ. (19R4). Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J. Gen. Virol. 75 (Pt 6):1457-1460.
62. Moore JP, Sodroski J. (1996). Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. Journal of Virology. 70:1863-1872.
63. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS. (2002). Broadly cross-reactive HIV-1-neutralizing human monoclonal Fabselected for binding to gp120-CD4-CCR5 complexes. Proceedings of the National Academy of Sciences of the United States of America. 99:6913-6918.
64. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML. (2000). Energetics of the HIV gp120-CD4 binding reaction. Proceedings of the National Academy of Sciences of the United States of America. 97:9026-9031.
65. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, Shibata R, Marlin MA. (2002). Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. Journal of Virology. 76:2123-2130.
66. Pal R, DeVico A. Rittenhouse S, Sarngadharan MG. (1993). Conformational perturbation of the envelope glycoprotein gp120 of human immunnodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A. Virology. 194:833-837.
67. Parren PWHI, Marx PA, Hessell AJ, Luckay A, Harouse. J Cheng-Mayer C, Moore JP, Burton DR. (2001). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. Journal of Virology. 75:8340-8347.
68. Platt EJ, Durnin JP, Kabat D. (2005). Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. Journal of Virology. 79:4347-4356.
69. Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S, Wang M, Parren PW, Burton DR. (2003). Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. Journal of Virology. 77:353-365.
70. Poignard P, Saphire EO. Parren PW, Burton DR. (2001). Gp120: biologic aspects of structural features. Annual Review of Immunology. 19:253-274.
71. Putney SD, Matthews TJ, Robey WG, Lynn DL, Robert-Guroff M, Mueller WT, Langlois AJ, Ghrayeb J, Petteway SR Jr., Weinhold KJ, Fischinger PJ, Wong-Staal F, Gallo RC, Bolognesi DP. (1986). HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science. 234:1392-1395.
72. Reeves JD, Hibbitts S, Simmons G, McKnight A, Azevedo-Pereira JM, Moniz-Pereira J, Clapham PR. (1999). Primary humah immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1, and simian immunodeficiency virus and relevance to cell tropism in vivo. Journal of Virology. 73:7795-7804.
73. Robinson JE, Elliott DH, Martin EA, Micken K, Rosenberg ES. (2005). High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection. Human Antibodies. 14:115-121.
74. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, Sfakianos JN, Mokili JL, Muldoon M, Mulenga J, Allen S, Hahn BH, Shaw GM, Blackwell JL, Korber BT, Hunter E, Derdeyn CA. (2007). Unique mutational patterns in the envelope alpha2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. Journal of Virology. 81:5658-5668.
75. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, Matthews TJ. (19$8). Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proceedings of the National Academy of Sciences of the United States of America. 85:3198-3202.
76. Saag MS, Hahn BH, Gibbons J, Li Y, Parks ES, Parks WP, Shaw GM. (1988). Extensive variation of human immunodeficiency virus type-1 in vivo. Nature. 334:440-444.
77. Sagar M, Kirkegaard E, Lavreys L, Overbaugh J. (2006). Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Research and Human Retroviruses. 22:430-437.
78. Sagar M, Wu X, Lee S, Overbaugh J. (2006). Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. Journal of Virology. 80:9586-9598.
79. Saha K, Yan H, Nelson JA, Zerhouni-Layachi B. (2005). Infection of human and non-human cells by a highly fusogenic primary CD4-independent HIV-1 isolate with a truncated envelope cytoplasmic tail. Virology. 337:30-44.
80. Salzwedel K, Smith ED, Dey B, Berger EA. (2000). Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. Journal of Virology. 74:326-333.
81. Sattentau QJ. (1996). Neutralization of HIV-1 by antibody. Current Opinions in Immunology. 8:540-545.
82. Sattentau QJ, Moore JP. (1991). Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. Journal of Experimental Medicine. 174:407-415.
83. Sattentau QJ, Moore JP. (1995). Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. Journal of Experimental Medicine. 182:185-196.
84. Sattentau QJ, Moore JP, Vignaux F, Traincard F, Poignard P. (1993). Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. Journal of Virology. 67:7383-7393.
85. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA. (1999). Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Medicine. 5:204-210.
86. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, Gershoni J, Robinson J, Moore JP, Sodroski J. (1998). CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. Journal of Virology. 72:4694-4703.
87. Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A. (2003). CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS. 17:291-300.
88. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. (1996). CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-186.
89. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowark MA, Hahn BH, Kwong P, Shaw GM. (2003) Antibody neutralization and escape by HIV-1. Nature. 422:307-312.
90. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. (1996). CD4-induced interaction of primary HIV-1 gp120 glyco-proteins with the chemokine receptor CCR-5. Nature. 384:179-183.
91. Wyatt R, Desjardin E, Olshevsky U, Nixon C, Binley J, Olshevsky V, Sodroski J. (1997). Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotin with the gp41 transmembrane glycoprotein. Journal of Virology. 71:9722-9731.
92. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:705-711.
93. Wyatt R, Sodroski J. (1998). The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:1884-1888.
94. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. (2002). Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Research and Human Retroviruses. 18:1207-1217.
95. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. (2002). Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Research and Human Retroviruses. 18:1207-1217.
96. Xiang SH, Farzan M, Si Z, Madani N, Wang L, Rosenberg E, Robinson J, Sodroski J. (2005). Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monocolonal antibody. Journal of Virology. 79:6068-6077.
97. Xiang SH, Wang L, Abreu M, Huang CC, Kwong PD, Rosenberg E, Robinson JE, Sodroski J. (2003). Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology. 315:124-134.
98. Yang X, Kurteva S, Lee S, Sodroski J. (2005). Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. Journal of Virology. 79:3500-3508.
99. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. (2005). Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. Journal of Virology. 79:12132-12147.
100. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. (2006). Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. Journal of Virology. 80:4388-4395.
101. Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE. (2006). Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. Journal of Virology. 80:3030-3041.
102. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD. (2006). Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathogens. 2:e83.
103. Zhang MY, Shu. Y, Rudolph D, Prabakaran P, Labrijn AF, Zwick MB, Lal RB, Dimitrov DS. (2004). Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. Journal of Molecular Biology. 335:209-219.
104. Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, Zolla-Pazner S, Flora MN, Quinnan GV, Jr. (2002). A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. Journal of Virology. 76:644-655.
105. Zhou T, Xu L, Dey B, Vessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD. (2007). Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 445:732-737.
106. Zhu P, Liu J, Bess J, Jr., Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. (2006). Distribution and three-dimensional structule of AIDS virus envelope spikes. Nature. 441:847-852.